Erik Berglund

Erik Berglund, M.D., Ph.D., R.A.C. has over 30 years of scientific, regulatory, and medical experience, including 18 years of regulatory affairs management, across the virology, CNS, neuroscience, oncology, and cardiovascular sectors. Dr. Berglund has extensive knowledge and experience generating regulatory strategies for clinical development and registration, managing complex regulatory filings, preparing and submitting regulatory filings in global markets, and supporting global clinical trials. Prior to joining VistaGen, Dr. Berglund served in various roles at Gilead Sciences, Inc. (Nasdaq: GILD), most recently as Senior Director, HIV Regulatory Affairs, where he was responsible for all regulatory aspects including leading regulatory project teams, supporting global clinical Phase 3 programs, and designing regulatory strategy for the INDs (U.S.), CTAs (E.U.), and global marketing application filings. Dr. Berglund previously held positions at Cato Research, Ltd.. (now Cato SMS) and Cato BioVentures Group. Dr. Berglund received his Medical Degree and Ph.D. in Medical Biochemistry and Biophysics from Umeå University, Sweden, and Regulatory Affairs Certification (R.A.C.) for both the U.S. and E.U.